Listen
CINRYZE
-
Opinions on drugs -
Posted on
Jun 20 2012
- Updated on
Jul 02 2012
Reason for request
Inclusion on the list of medicines approved for hospitals use.
-
Clinical Benefit
| Substantial |
The actual benefit of these proprietary medicinal products remains substantial in the Marketing Authorisation indications. |
Clinical Added Value
| no clinical added value |
In the management strategy for HAE, CINRYZE does not offer any improvement in the Actual Benefit (IAB V) compared to the other treatments already available. |
English version
Contact Us
Évaluation des médicaments
